-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...

-The Hindu KRISHNAGIRI: Over 300 Dalit families of Deveerahalli Village, of Kudimenahalli Panchayat, in Krishnagiri district allege that they are being denied work by intermediate castes of the village and of six other nearby villages. The reason behind this, they say, is that a Dalit youth in their area had fallen in love with a girl of an intermediate caste from Sathinayakkanpatti under Damodarahalli Panchayat. The girl is back with her parents...

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...

-The Hindu   "The court has recognised the right of patients to access affordable medicines over profits for big pharma companies" It was celebration time for health activists and civil society groups after the Supreme Court delivered its judgment dismissing Swiss multinational company Novartis' appeal for patent for its anti-cancer medicine imatinib mesylate or Gleevec. "We are happy that the apex court has recognised the right of patients to access affordable medicines over profits...